BR0114526A - Composições e métodos para reduzir as lipoproteinas(a) plasmáticas e os fatores de risco de doenças cardiovasculares - Google Patents

Composições e métodos para reduzir as lipoproteinas(a) plasmáticas e os fatores de risco de doenças cardiovasculares

Info

Publication number
BR0114526A
BR0114526A BR0114526-6A BR0114526A BR0114526A BR 0114526 A BR0114526 A BR 0114526A BR 0114526 A BR0114526 A BR 0114526A BR 0114526 A BR0114526 A BR 0114526A
Authority
BR
Brazil
Prior art keywords
methods
risk factors
compositions
disease risk
reducing plasma
Prior art date
Application number
BR0114526-6A
Other languages
English (en)
Inventor
Matthias Rath
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of BR0114526A publication Critical patent/BR0114526A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA REDUZIR AS LIPOPROTEìNAS (A) PLASMáTICAS E OS FATORES DE RISCO DE DOENçAS CARDIVASCULARES". A presente invenção provê composições e métodos para a redução dos níveis plasmáticos de Lp (a) em humanos. A presente invenção provê composições e métodos para a redução dos fatores de risco de doenças cardiovasculares. Além disso, esta invenção fornece alternativas terapêuticas para as intervenções farmacêuticas atuais para redução de colesterol, colesterol LDL, triglicérides e outros fatores metabólicos de risco.
BR0114526-6A 2000-10-03 2001-10-03 Composições e métodos para reduzir as lipoproteinas(a) plasmáticas e os fatores de risco de doenças cardiovasculares BR0114526A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23718600P 2000-10-03 2000-10-03
PCT/US2001/031203 WO2002028379A2 (en) 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases

Publications (1)

Publication Number Publication Date
BR0114526A true BR0114526A (pt) 2005-04-26

Family

ID=22892673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114526-6A BR0114526A (pt) 2000-10-03 2001-10-03 Composições e métodos para reduzir as lipoproteinas(a) plasmáticas e os fatores de risco de doenças cardiovasculares

Country Status (24)

Country Link
US (2) US6693129B2 (pt)
EP (1) EP1324753A2 (pt)
JP (1) JP2004525080A (pt)
KR (1) KR20030070003A (pt)
CN (1) CN100421659C (pt)
AU (2) AU1145202A (pt)
BR (1) BR0114526A (pt)
CA (1) CA2424880A1 (pt)
CZ (1) CZ20031167A3 (pt)
EE (1) EE200300136A (pt)
HR (1) HRP20030348A2 (pt)
HU (1) HUP0303040A3 (pt)
IL (2) IL155238A0 (pt)
MX (1) MXPA03002964A (pt)
NO (1) NO20031510L (pt)
NZ (2) NZ545806A (pt)
PL (1) PL212479B1 (pt)
RO (1) RO120567B1 (pt)
RU (1) RU2289406C2 (pt)
SK (1) SK5252003A3 (pt)
TR (1) TR200300594T2 (pt)
UA (1) UA77660C2 (pt)
WO (1) WO2002028379A2 (pt)
ZA (1) ZA200302772B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047682A1 (fr) * 2000-12-14 2002-06-20 Sankyo Company, Limited Composition ameliorant les lipides sanguins
CA2438063A1 (en) * 2001-02-27 2002-09-06 Nutrition 21, Inc. Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia
US20030054978A1 (en) * 2001-08-31 2003-03-20 Babish John G. Arginine compositions for coordinate modification of multiple cardiovascular risk factors
WO2004017913A2 (en) * 2002-08-22 2004-03-04 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
US20080020035A1 (en) * 2002-08-28 2008-01-24 Kedar Prasad Micronutrient formulations and related methods of manufacture
US7635469B2 (en) * 2002-08-28 2009-12-22 Premier Micronutrient Corporation Micronutrient formulations for hearing health
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
CA2503284A1 (en) * 2002-10-24 2004-05-06 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
CA2540202A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
JP2005225871A (ja) * 2004-01-16 2005-08-25 Sankyo Co Ltd 血中トリグリセライド又はホモシステインを低下させる医薬組成物
CA2572815A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
JP4896531B2 (ja) * 2005-01-25 2012-03-14 第一三共ヘルスケア株式会社 血中ＣｏＱ１０量を増加させる医薬組成物
US7628984B2 (en) * 2005-02-17 2009-12-08 Premier Micronutrient Corporation Micronutrient formulations for pulmonary and heart health
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
KR100592719B1 (ko) * 2005-10-05 2006-06-28 케이에스엠기술 주식회사 하천의 생태계 보호용 이물질 유입방지 시설
US20070292493A1 (en) * 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
US20080207748A1 (en) * 2007-02-22 2008-08-28 Innovation Labs, Inc. Vitamin c preparation
CA2681158C (en) 2007-03-13 2018-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2008139314A1 (en) * 2007-05-11 2008-11-20 Horphag Research (Luxembourg) Holding Sa Compositions and methods for treating joint disorders
CA2639895C (en) * 2007-10-05 2014-06-10 David Rowland Energizing compositions comprising goji, red clover and polygonum multiflorum, and uses thereof
RU2377007C1 (ru) * 2008-06-23 2009-12-27 Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М" Средство для лечения и профилактики онкологических заболеваний и способ применения этого средства (варианты)
US20110091618A1 (en) * 2009-10-16 2011-04-21 Frito-Lay North America, Inc. Method for preventing oxidation and off flavors in high carotenoid foods
RU2468791C2 (ru) * 2011-02-24 2012-12-10 Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" Композиция, обладающая адаптогенным, общеукрепляющим и повышающим работоспособность действием
EA025844B1 (ru) * 2012-05-08 2017-02-28 Общество С Ограниченной Ответственностью "Лигур-М" Средство для коррекции гиперхолестеринемии
EA201790017A1 (ru) * 2014-06-24 2017-06-30 Дедраф Холдинг Б.В. Новая минеральная композиция
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
EP3413900A1 (en) 2016-02-11 2018-12-19 Nutrition 21, LLC Chromium containing compositions for improving health and fitness
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
US11344575B2 (en) * 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
CA3035584A1 (en) 2016-09-01 2018-03-08 Jds Therapeutics, Llc Magnesium biotinate compositions and methods of use
SE540582C2 (en) * 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
EP3398601A1 (en) * 2017-05-02 2018-11-07 Salmon Pharma GmbH Nicotinamide for treating dyslipidemia
CN108033939B (zh) * 2017-12-26 2020-09-11 上海共晶医药科技有限公司 生育酚与脯氨酸的共结晶及其制备方法
CN109092262B (zh) * 2018-08-28 2019-07-05 广州达济医学科技有限公司 低密度脂蛋白吸附微球及制备方法和吸附材料
CN113329680A (zh) 2018-11-02 2021-08-31 营养21有限责任公司 用于改善视频游戏者认知功能的含有肌醇稳定的精氨酸硅酸盐复合物和肌醇的组合物
EP3883558A1 (en) * 2018-12-26 2021-09-29 Colgate-Palmolive Company Specific co-aggregation inhibition by arginine
GB2613672A (en) 2019-12-16 2023-06-14 Nutrition 21 Llc Methods of production of aginine-silicate complexes
WO2024003385A1 (en) 2022-07-01 2024-01-04 N.V. Nutricia Nutritional composition for neurodegeneration and neurotrauma

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356370A (en) * 1972-03-06 1974-06-12 Howard A N Methods and formulations for the treatment of obesity
US4414238A (en) * 1981-12-24 1983-11-08 Cutter Laboratories, Inc. Liquid elemental diet
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4891220A (en) * 1988-07-14 1990-01-02 Immudyne, Inc. Method and composition for treating hyperlipidemia
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5230996A (en) * 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
EP0891771A1 (en) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases
EP1068868A3 (en) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6361800B1 (en) * 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
ES2258426T3 (es) * 2000-06-16 2006-09-01 Matthias Dr. Med. Rath Composicion para la prevencion de enfermedades de los musculos lisos que comprenden ascorbato, arginina y magnesio.
ES2261136T3 (es) * 2000-10-09 2006-11-16 Matthias Dr. Med. Rath Composicion terapeutica de ascorbato con lisina y arginina para prevencion y tratamiento del cancer.
CH694549A5 (de) * 2001-01-16 2005-03-31 Dr Matthias Rath Verwendung einer synergistischen Zusammensetzung, die Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeration.
MXPA02010149A (es) * 2001-02-14 2004-08-19 Matthias Rath Composiciones de compuestos bioquimicos comprendidos en el metabolismo de bioenergia de las celulas y metodo de uso..
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells

Also Published As

Publication number Publication date
AU2002211452B2 (en) 2005-10-27
CZ20031167A3 (cs) 2003-12-17
ZA200302772B (en) 2004-10-18
TR200300594T2 (tr) 2004-10-21
RO120567B1 (ro) 2006-04-28
US20020094996A1 (en) 2002-07-18
NZ545806A (en) 2008-04-30
RU2289406C2 (ru) 2006-12-20
JP2004525080A (ja) 2004-08-19
CN1477959A (zh) 2004-02-25
WO2002028379A2 (en) 2002-04-11
SK5252003A3 (en) 2004-01-08
UA77660C2 (en) 2007-01-15
IL155238A0 (en) 2003-11-23
PL212479B1 (pl) 2012-10-31
MXPA03002964A (es) 2004-12-06
CA2424880A1 (en) 2002-04-11
NO20031510D0 (no) 2003-04-03
KR20030070003A (ko) 2003-08-27
US7244749B2 (en) 2007-07-17
WO2002028379A3 (en) 2003-02-27
IL185384A (en) 2008-06-05
HUP0303040A2 (hu) 2003-12-29
HRP20030348A2 (en) 2005-06-30
EE200300136A (et) 2003-08-15
PL365986A1 (en) 2005-01-24
AU1145202A (en) 2002-04-15
CN100421659C (zh) 2008-10-01
HUP0303040A3 (en) 2005-05-30
EP1324753A2 (en) 2003-07-09
US6693129B2 (en) 2004-02-17
US20040157895A1 (en) 2004-08-12
NO20031510L (no) 2003-06-02
NZ525390A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
BR0114526A (pt) Composições e métodos para reduzir as lipoproteinas(a) plasmáticas e os fatores de risco de doenças cardiovasculares
EP2332527A3 (en) Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2005005453A3 (en) Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
GT200500339A (es) Compuestos y derivados de dibencil amina
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
HUP0303083A2 (hu) CETP-gátló és atorvasztatin terápiás kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
GT199900147A (es) 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
HUP0004396A2 (hu) A lipoprotein-oxidáció gátlására szolgáló, hatóanyagként hidroxilezett koleszterincsökkentő szert tartalmazó gyógyszerkészítmények
DK1888080T3 (da) Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf
BRPI0408897A (pt) derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade
BR0016164A (pt) Composto,composição farmacêutica, uso de um composto, e, métodos para o tratamento e/ou profilaxia de asma, alergia, artrite, incluindo artrite reumatóide e espondiloartrite, gota, ateroesclerose, doença intestinal inflamatória crÈnica (doença de crohn), distúrbios dermatológicos inflamatórios e proliferativos, psorìase, dermatite atópica, uveìte, choque séptico, aids e osteoporose e para o tratamento de acne
WO2005096704A3 (en) Cholesterol lowering composition
EP1968561B8 (en) Treatment of diabetic nephropathy
BRPI0518300A2 (pt) derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
NO20071510L (no) 4-Amino-substituerte-2-substituerte-1,2,3,4-tetrahydrokinolinforbindelser
WO2006033891A3 (en) Compounds for the treatment of dyslipidemia and other lipid disorders
CO5690571A2 (es) Combinacion sinergica que comprende roflumilas y (r,r)-formoterol
EA200801815A1 (ru) Дибензиламиносоединения и производные
Fasipe et al. Exercise and vascular function in sedentary lifestyles in humans
UY29124A1 (es) Compuestos de quinolina
BRPI0607839A2 (pt) compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos
WO2005016277A3 (en) Arylsulfonamidobenzylic compounds
BR0308517A (pt) Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDA DES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.